Rena Conti, PhD


  • Proof of Paradigm in Cost-Effectiveness Analysis with Novel Therapeutics
  • Did the Medicare Modernization Act Cause Oncology Drug Shortages?
  • SPARQ/Center for Health Administration Studies
  • Alliance NCORP Research Base-Clinical Trials (Non-Alliance)


  • Kenyon College, Gambier, OH BA 05/1992 Philosophy
  • Harvard University, Cambridge, MA PhD 06/2006 Health Policy (Economics)


  • CONTI RM, MB Rosenthal, B Polite, PB Bach, Y-C T Shih. “Infused chemotherapy use following patent expiration among individuals aged 65 and older,” American Journal of Managed Care. May 2012, 18(5 SP 2):e173-8 (1 Chart, 2 Graphs).
  • CONTI RM, AC Bernstein, VM Villaflor, RL Schilsky, MB Rosenthal, PB Bach. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists,” Journal of Clinical Oncology. 2013 Mar 20;31(9):1134-9. doi: 10.1200/JCO.2012.42.7252. Epub 2013 Feb 19. PubMed PMID: 23423747; PubMed Central PMCID: PMC3595423.
  • Howard D, PB Bach, ER Berndt, RM CONTI. “Pricing in the Market for Anticancer Drugs,” Journal of Economic Perspectives. 2015;29(1,Winter):139–162.
  • CONTI RM, ER Berndt. “Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007,” Advances in CRIW Conference Proceedings. Forthcoming Summer 2015.
  • CONTI RM, MR Rosenthal. “Pharmaceutical Policy Reform — Balancing Affordability with Incentives for Innovation.” New England Journal of Medicine, February 25, 2016; 374;8.
  • Bach PB, RM CONTI, G Schnorr, R Muller, L Saltz. “Overspending driven by oversized single dose vials of cancer drugs.” British Medical Journal, March 1, 2016;352:i788.
  • Padula WV, RA Larson, SB Dusetzina, JF Apperley, M Baccarani, E Eigendorff, F Guilhot, J Guilhot, F-X Mahon, G Martinelli, J Mayer, MC Mueller, D Niederwieser, S Saussele, CA Schiffer, RT Silver, B Simonsson, R Hehlmann, RM CONTI. “Estimating the cost-effectiveness of tyrosine kinase inhibitor treatment strategies for newly diagnosed chronic myeloid leukemia in chronic phase following imatinib’s generic entry in the U.S.” Journal of National Cancer Institute, March 4, 2016 [Epub ahead of print]